Immunotherapy / PD-1 inhibitorFDA-approvedSecond-line
Durvalumab
How it works
Durvalumab is an antibody that blocks the PD-1 receptor on immune cells, allowing them to attack cancer cells.
Cancer types
Lung Cancer— All patients
Colorectal Cancer— All patients
Pancreatic Cancer— All patients
Ovarian Cancer— All patients
Efficacy
In clinical trials, durvalumab improved overall survival in patients with pancreatic cancer, with a median overall survival of approximately 11.3 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Shows Promise for Lung Cancer Patients | Lung Cancer | phase-2 | The combination regimen demonstrated an objective response rate of 73.3% and a median overall survival of 14.6 months. | Source → |
| Durvalumab's Effectiveness in Lung Cancer Treatment | Lung Cancer | meta-analysis | — | Source → |
| New Study Compares Lung Cancer Treatments | Lung Cancer | phase-3 | Median IRF-assessed PFS in PD-L1+ patients was 19.4 months with tiragolumab plus atezolizumab versus 16.6 months with durvalumab. | Source → |
| Testing Durvalumab and Tremelimumab for Non-Small-Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Study Tests Treatment for Rare Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Durvalumab Improves Lung Cancer Survival in Real-World Study | Lung Cancer | observational | Median progression-free survival was 18.6 months with durvalumab consolidation, compared to 7.5 months without. | Source → |
| Testing New Treatments for Aggressive Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Testing Ceralasertib and Durvalumab in Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Durvalumab Shows Promise in Treating Early-Stage Lung Cancer | Lung Cancer | meta-analysis | Durvalumab treatment showed a significant trend toward improvement of event-free survival (HR 0.69; 95% CI: 0.61-0.78; I = 0%). | Source → |
| Testing Olaparib and Durvalumab in HER2 Negative BRCAm Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Long-term response to cancer treatment in older adult | Lung Cancer | observational | — | Source → |
| Testing Ceralasertib and Durvalumab for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Durvalumab Improves Survival in Some Lung Cancer Patients | Lung Cancer | observational | Median overall survival was 27.3, 15.1, and 23.4 months for PD-L1-positive patients with and without durvalumab and PD-L1-negative patients, respectively. | Source → |
| Testing NKTR-255 and Durvalumab in Lung Cancer Patients After Chemoradiotherapy | Lung Cancer | phase-2 | — | Source → |
| Ovarian Cancer Study Examines Durvalumab and Chemotherapy Combination | Ovarian Cancer | phase-1 | — | Source → |
| Durvalumab and Chemotherapy Combination for Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Calderasib and Durvalumab Tested in Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Lung Cancer Treatment Shows Promise in Real-World Study | Lung Cancer | observational | The median progression-free survival was 16.0 months, and the median overall survival was 37.5 months. | Source → |
| New Insights into Lung Cancer Treatment with Durvalumab | Lung Cancer | observational | The median progression-free survival in the overall population was 24.2 months, and the 3-year progression-free survival rate was 38.9%. | Source → |
| Testing a Combination Treatment for Advanced Triple-Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Tarlatamab and ZL-1310 in Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Investigating Durvalumab and Oleclumab for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Savolitinib and Durvalumab Combination for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Durvalumab After Chemoradiation Therapy for Limited Stage Small-Cell Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Testing Durvalumab and Radiation Therapy for Early-stage Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Chemo-Immunotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Durvalumab Side Effects in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Testing Durvalumab and Tremelimumab in Metastatic Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing New Treatments for Advanced Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Testing Durvalumab and Radiation Therapy in Early Stage Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Durvalumab Maintenance in Frail Small Cell Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
| Assessing Durvalumab and Domvanalimab in Stage III Unresectable NSCLC | Lung Cancer | phase-3 | — | Source → |
| Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Durvalumab, Trastuzumab, and Pertuzumab in HER2-Enriched Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Ceralasertib in Combination with Other Treatments for Various Cancers | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy for Resectable Pancreatic Cancer Before Surgery | Pancreatic Cancer | phase-2 | — | Source → |
| Study of AZD2811 and Durvalumab in Small-Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Evaluating Pumitamig and Durvalumab in Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Testing Radiotherapy and Immunotherapy for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| New Cancer Treatment Combination Shows Promise in Lung and Head and Neck Cancers | Lung Cancer | phase-1 | Five (8.3%) patients had objective responses; 31 (51.7%) had stable disease. | Source → |
| Durvalumab as Consolidation for Limited Stage Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Combining two treatments for advanced prostate cancer | Prostate Cancer | phase-2 | Median radiographic progression-free survival was 5.0 months, and median overall survival was 19.1 months. | Source → |
| Durvalumab and Chemotherapy Tested in Lung Cancer Patients | Lung Cancer | phase-2 | Confirmed ORR was 16% (80% confidence interval: 7-30); response was maintained for more than 6 months in the four patients with confirmed response. | Source → |
| Triplet Combination of Targeted Immunotherapeutic Agents for Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Durvalumab's Effect on Lung Cancer Recurrence After Chemotherapy and Radiation | Lung Cancer | phase-3 | Durvalumab receipt was associated with improved PFS (median 16 vs. 11 months, P = .011) and improved OS (median 50 vs. 30 months, P = .042). | Source → |
| Durvalumab Study for Unresectable Lung Cancer in Russia | Lung Cancer | preclinical | — | Source → |
| Combining Chemotherapy and Immunotherapy for Lung Cancer | Lung Cancer | phase-2 | N2 nodal clearance was 73.3% (22/30) after treatment. | Source → |
| Advanced Lung Cancer Treatment Study Underway | Lung Cancer | phase-3 | — | Source → |
| Pancreatic Cancer Treatment Trial | Pancreatic Cancer | phase-1 | — | Source → |
| Trial Tests Cancer Treatments | Colorectal Cancer | phase-2 | — | Source → |
| Durvalumab treatment linked to pneumonitis risk in lung cancer patients | Lung Cancer | observational | — | Source → |
| Durvalumab-Induced Lung Injury Complicated by Human Metapneumovirus Infection | Lung Cancer | observational | — | Source → |
| Timing of Durvalumab Treatment Affects Lung Cancer Survival | Lung Cancer | observational | When considering the timing of durvalumab, no significant survival difference was found when durvalumab was initiated on or before week 4: adjusted HR, 0.81 (95% CI, 0.62 to 1.05, = .07). | Source → |
| New Treatment Combination Shows Promise for Ovarian Cancer Patients | Ovarian Cancer | phase-2 | PFS36 rates are 47.4% (olaparib priming then olaparib-durvalumab), 48.7% (olaparib-cyclophosphamide then olaparib-durvalumab), and 35.1% (olaparib monotherapy). | Source → |
| Durvalumab and Radiation Therapy Improve Lung Cancer Outcomes | Lung Cancer | phase-3 | The 2- and 3-year local control rates in patients who received total radiation doses > 66 Gy were 80% and 75%, respectively. | Source → |
| Rare Cancer Linked to New Lung Cancer Treatment | Leukemia | observational | — | Source → |
| Durvalumab as Consolidation Therapy for Lung Cancer Patients in Brazil | Lung Cancer | observational | Median progression-free survival was 9.9 months, with a 36 month-PFS of 34.5%. | Source → |
| New Lung Cancer Treatment Shows Promise After Surgery | Lung Cancer | observational | The IPTW-adjusted median progression-free survival was 25.4 months for the CRT-D group, and 11.5 months for the CRT group. | Source → |
| Durvalumab with Radiation Therapy in Lung Cancer: Early Results | Lung Cancer | phase-2 | The primary endpoint of progression-free survival at 12 months was 20%. | Source → |
| Durvalumab Outcomes in Stage III Lung Cancer Patients | Lung Cancer | observational | The 4-year overall survival rate was 53% overall, and 67% for patients with a PD-L1 score of ≧50%. | Source → |
| Durvalumab treatment for lung cancer patients shows promising results | Lung Cancer | observational | Median progression-free survival was 16.7 months (95% CI 12.2-25). | Source → |
| Durvalumab Works in Elderly Lung Cancer Patients, but Side Effects are More Common | Lung Cancer | observational | The median progression-free survival was 17.7 months in patients aged 70 years or older, and 19.4 months in younger patients. | Source → |
| New Trial Explores Combination Therapy for Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Biomarker May Predict Lung Cancer Treatment Side Effect | Lung Cancer | lab-study | Patients with high levels of EV-RELA had a 53.8% incidence of symptomatic pneumonitis, compared to 13.4% in those with low levels. | Source → |
| Durvalumab Linked to Rare Neurological Side Effects in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Combining Eribulin and Durvalumab in Advanced Breast and Ovarian Cancer | Ovarian Cancer | phase-1/2 | The overall response rate was 55%, and median progression-free survival was 6.2 months, with median overall survival of 15.0 months. | Source → |
| Durvalumab Efficacy Similar in Black and Non-Black Lung Cancer Patients | Lung Cancer | phase-3 | The median overall survival was not-reached in Black patients and 39.7 months in non-Black patients. | Source → |
| Durvalumab and Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer | Breast Cancer | phase-1/2 | pCR rates were similar between Black (43%) and non-Black patients (48%; P = 0.71). | Source → |
| Researchers Treat Pneumonitis with Infliximab in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Durvalumab-based treatment helps some patients with lung cancer transformation | Lung Cancer | observational | — | Source → |
| Hispanic Patients with Lung Cancer May Have Poorer Outcomes with Durvalumab Treatment | Lung Cancer | observational | Hispanic patients had a 20% reduction in survival compared to non-Hispanic White patients and a 42% reduction compared to the PACIFIC trial group. | Source → |
| Durvalumab after Chemotherapy and Radiation Works in Real-World Lung Cancer Patients | Lung Cancer | meta-analysis | The pooled 12-month overall survival rate was 90% (95% confidence interval [CI], 83%-98%) and the pooled 12-month progression-free survival rate was 62% (95% CI, 56%-68%). | Source → |
| Combining two treatments shows promise for melanoma patients | Melanoma | phase-2 | The overall response rate was 31.0% and the disease control rate was 63.3%. | Source → |
| Combining Immunotherapies to Treat Colorectal Cancer Liver Metastases | Colorectal Cancer | phase-1 | The median relapse-free survival was 9.7 months, and overall survival was 24.5 months. | Source → |
| Durvalumab May Not Be as Effective for Some Lung Cancer Patients | Lung Cancer | observational | Patients in the ERBB2/EGFR cohort had a significantly shorter disease-free survival compared with the EGFR or ERBB2 wild-type cohort (7.5 mo versus not reached, p = 0.04). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.